The U.S. Supreme Court rejected CareDx's appeal regarding patents related to organ-rejection tests, affirming the lower court's decision. CareDx accused Natera and Viracor of infringing on its patents for kidney transplant monitoring tests. The Court of Appeals ruled the patents invalid, citing unpatentable natural phenomena. The issue of patent eligibility in medical diagnostics remains contentious.
Başka Bir Dile
kaynak içeriğinden
www.medscape.com
Önemli Bilgiler Şuradan Elde Edildi
by Blake Britta... : www.medscape.com 10-02-2023
http://www.medscape.com/viewarticle/996999Daha Derin Sorular